{"filing":{"accession_number":"0001193125-26-316766","cik":"0001419041","ticker":"FBRX","company_name":"Forte Biosciences, Inc.","form":"8-K","filing_date":"2026-07-27","report_date":"2026-07-26","primary_document":"d31466d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312526316766/d31466d8k.htm"},"events":[{"id":20579,"run_id":18523,"accession_number":"0001193125-26-316766","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"Forte Biosciences entered into an Agreement and Plan of Merger with argenx BV on July 26, 2026, providing for acquisition of the Company at $77.00 per share in cash, representing approximately $2.2 billion in total equity value. The transaction consists of a tender offer followed by a merger under Delaware law, with Forte becoming a wholly owned subsidiary of argenx.","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-07-27","form":"8-K","submitted_at":null,"items":[{"id":19987,"accession_number":"0001193125-26-316766","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Forte Biosciences entered into an Agreement and Plan of Merger with argenx BV on July 26, 2026, providing for acquisition of the Company at $77.00 per share in cash, representing approximately $2.2 billion in total equity value. The transaction consists of a tender offer followed by a merger under Delaware law, with the Company becoming a wholly owned subsidiary of argenx. This is a material acquisition transaction requiring Item 1.01 disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T10:08:13.480644+00:00","company_name":"","ticker":null,"filing_date":""},{"id":19988,"accession_number":"0001193125-26-316766","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"The filing discloses execution of a definitive merger agreement under which argenx will acquire Forte Biosciences for $77 per share in cash, representing approximately $2.2 billion in total equity value. This is a material acquisition transaction requiring disclosure under Item 1.01 of Form 8-K, disclosed here via Item 7.01 (Regulation FD Disclosure) with the press release attached as Exhibit 99.1. The transaction is a clear entry into a material M\u0026A activity with substantial financial impact to the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T10:08:13.480644+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19987,"accession_number":"0001193125-26-316766","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Forte Biosciences entered into an Agreement and Plan of Merger with argenx BV on July 26, 2026, providing for acquisition of the Company at $77.00 per share in cash, representing approximately $2.2 billion in total equity value. The transaction consists of a tender offer followed by a merger under Delaware law, with the Company becoming a wholly owned subsidiary of argenx. This is a material acquisition transaction requiring Item 1.01 disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T10:08:13.480644+00:00","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-07-27"},{"id":19988,"accession_number":"0001193125-26-316766","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"The filing discloses execution of a definitive merger agreement under which argenx will acquire Forte Biosciences for $77 per share in cash, representing approximately $2.2 billion in total equity value. This is a material acquisition transaction requiring disclosure under Item 1.01 of Form 8-K, disclosed here via Item 7.01 (Regulation FD Disclosure) with the press release attached as Exhibit 99.1. The transaction is a clear entry into a material M\u0026A activity with substantial financial impact to the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-27T10:08:13.480644+00:00","company_name":"Forte Biosciences, Inc.","ticker":"FBRX","filing_date":"2026-07-27"}]}